[A case of recurrent esophageal cancer successfully treated with weekly paclitaxel in combination with radiotherapy].
A 48-year-old man underwent subtotal esophagectomy for pStage III (pT 3 pN 3) thoracic esophageal carcinoma on June 20, 2002, in combination with chemotherapy (5-FU 500 mg/day day 1-14, CDDP 10 mg/day day 1-14, VDS 3 mg on days 1 and 8) before and after the operation. Recurrence was seen 7 months after the operation in right pleura and lower mediastinum. Chemo (same regimen)-radiotherapy (50 Gy) was then performed but without effect. Thereafter, lung and upper mediastinal metastases were found, and weekly administration of paclitaxel (70 mg/m2, day 1, 8, 15, q 4w) was initiated in combination with radiotherapy (40 Gy). Two cycles of treatment resulted in PR, and CR was achieved after the 8th cycle was completed. Although treatment was terminated after the 12 th cycle due to development of peripheral neuropathy (grade 2), CR was still maintained 8 months after the completion of treatment. These results suggested the effectiveness of the treatment in cases that show resistance to conventional 5-FU-based chemotherapy.
Hara
Takuo
T
Dept. of Surgery, Kouseiren Takaoka Hospital.
Hirano
Makoto
M
Nozawa
Hiroshi
H
Nakada
Koichi
K
Hirano
Yasumitsu
Y
Oyama
Kaeko
K
Hada
Tadahiro
T
Takagi
Takeshi
T
Kikkawa
Hirokatsu
H
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D016629:Esophagectomy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011879:Radiotherapy Dosage; D012074:Remission Induction
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel